OMER Logo

Omeros Corporation (OMER) 

NASDAQ
Market Cap
$625.86M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
647 of 775
Rank in Industry
352 of 433

Largest Insider Buys in Sector

OMER Stock Price History Chart

OMER Stock Performance

About Omeros Corporation

Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for …

Insider Activity of Omeros Corporation

Over the last 12 months, insiders at Omeros Corporation have bought $0 and sold $0 worth of Omeros Corporation stock.

On average, over the past 5 years, insiders at Omeros Corporation have bought $40,500 and sold $1.56M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 15,000 shares for transaction amount of $25,200 was made by Demopulos Gregory A MD (Chairman, CEO & President) on 2023‑11‑17.

List of Insider Buy and Sell Transactions, Omeros Corporation

2023-11-17PurchaseChairman, CEO & President
15,000
0.0245%
$1.68$25,200+131.29%
2023-11-15Purchasedirector
10,000
0.0161%
$1.53$15,300+147.21%
2023-05-22Saledirector
5,000
0.0081%
$6.53$32,650-45.85%
2023-05-22Saledirector
5,000
0.008%
$6.46$32,300-45.85%
2021-06-17SaleCHAIRMAN, CEO & PRESIDENT
36,857
0.0588%
$14.90$549,169-53.84%
2021-06-15SaleCHAIRMAN, CEO & PRESIDENT
36,856
0.0596%
$15.02$553,577-53.29%
2021-05-20SaleCHAIRMAN, CEO & PRESIDENT
36,856
0.0584%
$14.96$551,366-51.92%
2021-05-19SaleCHAIRMAN, CEO & PRESIDENT
36,857
0.0594%
$17.07$629,149-57.10%
2021-04-08SaleCHAIRMAN, CEO & PRESIDENT
35,206
0.0566%
$17.76$625,259-53.90%
2021-04-07SaleCHAIRMAN, CEO & PRESIDENT
37,407
0.0599%
$17.91$669,959-54.24%
2021-02-22SaleVP FINANCE AND CAO
8,100
0.0134%
$23.28$188,568-34.89%
2021-02-19SaleVP FINANCE AND CAO
10,000
0.0155%
$22.64$226,400-37.23%
2021-02-10SaleVP FINANCE AND CAO
1,900
0.0031%
$22.49$42,731-32.76%
2021-01-19SaleVP FINANCE AND CAO
9,500
0.0157%
$19.95$189,525-21.58%
2021-01-13Saledirector
5,000
0.008%
$16.97$84,850-10.19%
2020-05-13Saledirector
5,000
0.0093%
$14.40$71,999+4.28%
2019-12-03Saledirector
20,000
0.0309%
$10.99$219,748-6.68%
2019-10-14Saledirector
10,000
0.0205%
$15.12$151,180-7.99%
2018-08-31SaleVP Patent and General Counsel
15,058
0.0308%
$25.75$387,691-39.01%
2018-08-30SaleVP Patent and General Counsel
70,000
0.0825%
$14.28$999,250-36.44%

Insider Historical Profitability

<0.0001%
Demopulos Peter A MDdirector
208516
0.3598%
$10.8070<0.0001%
Aspiri Raydirector
186872
0.3225%
$10.8010<0.0001%
Demopulos Gregory A MDChairman, CEO & President
123945
0.2139%
$10.80112
HANISH ARNOLD Cdirector
0
0%
$10.8011+0.81%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Ingalls Snyder Llc$16.21M8.114.7M+3.33%+$522,267.540.76
BlackRock$14.53M7.274.21M-1.61%-$237,063.30<0.0001
The Vanguard Group$11.21M5.613.25M+2.57%+$280,650.60<0.0001
Stifel$6.59M3.31.91M+0.98%+$63,669.860.01
D. E. Shaw & Co.$5.79M2.91.68M+12.42%+$639,560.960.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.